Eric McDade

Generating author description...

All published works

Action	Title	Year	Authors
+	MRI and PET findings with long‐term gantenerumab treatment: results from the DIAN‐TU trial	2024	Tammie L.S. Benzinger Brian A. Gordon Austin McCullough Russ C. Hornbeck Shaney Flores Robert A. Koeppe Clifford R. Jack Yan Li Eric McDade Jorge J. Llibre‐Guerra
+	Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data	2024	Guoqiao Wang Jason Hassenstab Yan Li Andrew J. Aschenbrenner Eric McDade Jorge J. Llibre‐Guerra Randall J. Bateman Chengjie Xiong
+	Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease	2024	David M. Cash Katy E. Morgan Antoinette O’Connor Thomas Veale Ian B. Malone Teresa Poole Tammie L.S. Benzinger Brian A. Gordon Laura Ibáñez Yan Li
+ PDF Chat	Statistical considerations when estimating time‐saving treatment effects in Alzheimer's disease clinical trials	2024	Guoqiao Wang Gary Cutter Neil P. Oxtoby Guogen Shan Whedy Wang Brian Mangal Yijie Liao Jorge J. Llibre‐Guerra Li Y Chengjie Xiong
+	Novel non‐linear models for clinical trial analysis with longitudinal data: A tutorial using <scp>SAS</scp> for both frequentist and Bayesian methods	2024	Guoqiao Wang Whedy Wang Brian Mangal Yijie Liao Lon S. Schneider Yan Li Chengjie Xiong Eric McDade Richard Kennedy Randall J. Bateman
+	Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials	2024	Haiyan Liu Jonathan Li Ellen Ziegemeier Sarah F. Adams Eric McDade David B. Clifford Yuping Cao Guoping Wang Yuguo Li Susan L. Mills
+ PDF Chat	Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease	2024	Guoqiao Wang Yan Li Chengjie Xiong Tammie L.S. Benzinger Brian A. Gordon Jason Hassenstab Andrew J. Aschenbrenner Eric McDade David B. Clifford Jorge J. Libre‐Guerra
+ PDF Chat	Alternative Endpoints and Models for AD Prevention Trials	2023	Guoqiao Wang Yan Li Chengjie Xiong Eric McDade Randall J. Bateman
+	Evaluation of the performance of alternative models in analyzing longitudinal data for Alzheimer clinical trials compared to MMRM	2022	Guoqiao Wang Yan Li Chengjie Xiong Lei Liu Richard Kennedy Lon S. Schneider Fanni Natanegara Eric McDade Randall J. Bateman
+	Sample size estimation for clinical trials with tau‐PET SUVR as the primary outcome in dominantly inherited Alzheimer’s disease	2021	Guoqiao Wang Yan Li Chengjie Xiong Tammie L.S. Benzinger Brian A. Gordon Jason Hassenstab Andrew J. Aschenbrenner Anne M. Fagan Kelley A. Coalier Eric McDade
+ PDF Chat	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	2021	Eric McDade Iryna Voytyuk Paul Aisen Randall J. Bateman María C. Carrillo Bart De Strooper Christian Haass Eric M. Reiman Reisa A. Sperling Pierre N. Tariot
+ PDF Chat	Gantenerumab in‐depth outcomes	2020	Stephen Salloway Randall J. Bateman Andrew J. Aschenbrenner Tammie L.S. Benzinger David B. Clifford Kelley A. Coalier Carlos Cruchaga Anne M. Fagan Martin R. Farlow Alison Goate
+ PDF Chat	Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab	2020	Randall J. Bateman Andrew J. Aschenbrenner Tammie L.S. Benzinger David B. Clifford Kelley A. Coalier Carlos Cruchaga Anne M. Fagan Martin R. Farlow Alison Goate Brian A. Gordon
+	O1‐09‐02: TWO‐PERIOD LINEAR MIXED EFFECTS PRIMARY ANALYSIS MODEL FOR CLINICAL TRIALS WITH RUN‐IN DATA FOR ALZHEIMER DISEASE	2019	Guoqiao Wang Andrew J. Aschenbrenner Yan Li Eric McDade Lei Liu Tammie L.S. Benzinger Randall J. Bateman John C. Morris Jason Hassenstab Scott Berry
+	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies	2019	Yi Su Shaney Flores Guoqiao Wang Russ C. Hornbeck Benjamin Speidel Nelly Joseph‐Mathurin Andrei G. Vlassenko Brian A. Gordon Robert A. Koeppe William E. Klunk
+ PDF Chat	Two‐period linear mixed effects models to analyze clinical trials with run‐in data when the primary outcome is continuous: Applications to Alzheimer's disease	2019	Guoqiao Wang Andrew J. Aschenbrenner Yan Li Eric McDade Lei Liu Tammie L.S. Benzinger Randall J. Bateman John C. Morris Jason J. Hassenstab Chengjie Xiong
+ PDF Chat	O1‐02‐03: DIAN‐TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA	2018	Randall J. Bateman Susan Mills Anna Santacruz Martin R. Farlow Stephen Salloway John C. Morris Tammie L.S. Benzinger Anne M. Fagan Alison Goate Jason Hassenstab
+ PDF Chat	P2‐072: A STATISTICAL METHOD FOR DETERMINING BIOMARKER THRESHOLD FOR ALZHEIMER'S DISEASE	2018	Yan Li Guoqiao Wang Chengjie Xiong Eric McDade Anne M. Fagan Brian A. Gordon Tammie L.S. Benzinger Andrew J. Aschenbrenner Jason Hassenstab Randall J. Bateman
+	P2‐076: A NOVEL ALTERNATIVE MODEL TO MMRM AS THE PRIMARY MODEL FOR SPORADIC AD CLINICAL TRIALS: THE PROPORTIONAL MMRM	2018	Guoqiao Wang Chengjie Xiong Eric McDade Yan Li Andrew J. Aschenbrenner Jason Hassenstab Scott Berry Randall J. Bateman
+ PDF Chat	A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease	2018	Guoqiao Wang Scott Berry Chengjie Xiong Jason Hassenstab Melanie Quintana Eric McDade Paul Delmar Matteo Vestrucci Gopalan Sethuraman Randall J. Bateman
+ PDF Chat	The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model	2016	Randall J. Bateman Tammie L.S. Benzinger Scott Berry David B. Clifford Cynthia Duggan Anne M. Fagan Kathleen Fanning Martin R. Farlow Jason Hassenstab Eric McDade
+ PDF Chat	P4‐004: Planning Dose Escalation in Phase III Clinical Trials May Prevent Underpowered Trials and Mitigate the Increase in Sample Size or Duration of Adaptive Trials	2016	Guoqiao Wang Eric McDade Randall J. Bateman Jason Hassenstab Martin R. Farlow Stephen Salloway Richard Kennedy Lon S. Schneider Scott Berry Chengjie Xiong
+ PDF Chat	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial	2013	Susan Mills J. Mallmann Anna Santacruz A. Fuqua María M. Gómez Carril P.S. Aisen Matthew C. Althage S. Belyew Tammie L.S. Benzinger William S. Brooks

Common Coauthors

Coauthor	Papers Together
Randall J. Bateman	22
Guoqiao Wang	19
Tammie L.S. Benzinger	13
Chengjie Xiong	12
Jason Hassenstab	12
Andrew J. Aschenbrenner	9
Brian A. Gordon	8
Martin R. Farlow	7
Anne M. Fagan	7
Anna Santacruz	7
John C. Morris	7
William S. Brooks	6
Stephen Salloway	6
Jorge J. Llibre‐Guerra	6
Catherine J. Mummery	5
Raquel Sánchez‐Valle	5
David B. Clifford	5
Clifford R. Jack	5
Colin L. Masters	5
Paul Delmar	5
Christopher H. van Dyck	5
Lon S. Schneider	5
Lawrence S. Honig	5
Scott Berry	5
Sarah B. Berman	4
Roger Clarnette	4
Suman Jayadev	4
Robert A. Koeppe	4
Mario Masellis	4
Serge Gauthier	4
Ging‐Yuek Robin Hsiung	4
David Wallon	4
Didier Hannequin	4
Erik D. Roberson	4
Alison Goate	4
Jérémie Pariente	4
Mathias Jucker	3
Ghulam M. Surti	3
Rachelle S. Doody	3
Geoffrey A. Kerchner	3
John M. Ringman	3
Ivonne Z. Jiménez‐Velázquez	3
Susan Mills	3
Florence Pasquier	3
Nick C. Fox	3
Chengjie Xiong	3
Maïté Formaglio	3
Susan Mills	3
Kelley A. Coalier	3
Richard Kennedy	3

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model	2016	Randall J. Bateman Tammie L.S. Benzinger Scott Berry David B. Clifford Cynthia Duggan Anne M. Fagan Kathleen Fanning Martin R. Farlow Jason Hassenstab Eric McDade	5
+ PDF Chat	A novel cognitive disease progression model for clinical trials in autosomal‐dominant Alzheimer's disease	2018	Guoqiao Wang Scott Berry Chengjie Xiong Jason Hassenstab Melanie Quintana Eric McDade Paul Delmar Matteo Vestrucci Gopalan Sethuraman Randall J. Bateman	5
+ PDF Chat	Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease	2022	Guoqiao Wang Lei Liu Yan Li Andrew J. Aschenbrenner Randall J. Bateman Paul Delmar Lon S. Schneider Richard Kennedy Gary Cutter Chengjie Xiong	4
+ PDF Chat	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial	2013	Susan Mills J. Mallmann Anna Santacruz A. Fuqua María M. Gómez Carril P.S. Aisen Matthew C. Althage S. Belyew Tammie L.S. Benzinger William S. Brooks	3
+	Applied Longitudinal Analysis	2011	Garrett M. Fitzmaurice Nan M. Laird James H. Ware	2
+	Flexible regression models with cubic splines	1989	Sylvain Durrleman Richard Simon	2
+	On Efficiency of Constrained Longitudinal Data Analysis Versus Longitudinal Analysis of Covariance	2009	Kaifeng Lu	2
+	Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run‐in period increase efficiency?	2008	Chris Frost Michael G. Kenward Nick C. Fox	2
+	Size and Power of Two-Sample Tests of Repeated Measures Data	1993	Jeffrey D. Dawson Stephen W. Lagakos	1
+	Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force	2013	Bruno Vellas María C. Carrillo Cristina Sampaio H. Robert Brashear Eric Siemers Harald Hampel Lon S. Schneider Michael W. Weiner Rachelle S. Doody Zaven S. Khachaturian	1
+ PDF Chat	Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment	2015	Guoqiao Wang Richard Kennedy Gary Cutter Lon S. Schneider	1
+ PDF Chat	Combining Multiple Markers to Improve the Longitudinal Rate of Progression: Application to Clinical Trials on the Early Stage of Alzheimer's Disease	2013	Chengjie Xiong Gerald van Belle Kewei Chen Lili Tian Jingqin Luo Feng Gao Ying Yan Ling Chen John C. Morris Paul K. Crane	1
+	Sampling-Based Approaches to Calculating Marginal Densities	1990	Alan E. Gelfand A. F. M. Smith	1
+	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design	1994	Stephen Senn Lars Frison Stuart J. Pocock	1
+	Charting a path toward combination therapy for Alzheimer’s disease	2014	Diane Stephenson D.F. Perry Cynthia Bens Lisa J. Bain Donald A. Berry Michael Krams Reisa A. Sperling David M. Dilts Johan Luthman Debra Hanna	1
+	F4‐03‐02: Delayed‐start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease	2015	Hong Liu‐Seifert Paul Aisen Scott W. Andersen Karen C. Holdridge Eric Siemers	1
+	Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development	2017	Milton Packer	1
+ PDF Chat	Design optimization for clinical trials in early‐stage manifest Huntington's disease	2017	Chris Frost Amy Mulick Rachael I. Scahill Gail Owen Elizabeth Aylward Blair R. Leavitt Alexandra Dürr Raymund A.C. Roos Beth Borowsky Julie C. Stout	1
+	P4‐389: ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE‐2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD‐TO‐MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE	2018	Shau Yu Lynch June Kaplow Jim Zhao Shobha Dhadda Johan Luthman Bruce Albala	1
+ PDF Chat	A review of spline function procedures in R	2019	Aris Perperoglou Willi Sauerbrei Michał Abrahamowicz Matthias Schmid	1
+ PDF Chat	Determining clinically meaningful decline in preclinical Alzheimer disease	2019	Philip S. Insel Michael W. Weiner R. Scott Mackin Elizabeth C. Mormino Yen Ying Lim Erik Stomrud Sebastian Palmqvist Colin L. Masters Paul Maruff Oskar Hansson	1
+ PDF Chat	Two‐period linear mixed effects models to analyze clinical trials with run‐in data when the primary outcome is continuous: Applications to Alzheimer's disease	2019	Guoqiao Wang Andrew J. Aschenbrenner Yan Li Eric McDade Lei Liu Tammie L.S. Benzinger Randall J. Bateman John C. Morris Jason J. Hassenstab Chengjie Xiong	1
+	The relative efficiency of time‐to‐progression and continuous measures of cognition in presymptomatic Alzheimer's disease	2019	Dan Li Samuel Iddi Paul Aisen Wesley K. Thompson Michael Donohue	1
+ PDF Chat	Power and sample size for random coefficient regression models in randomized experiments with monotone missing data	2021	Nan Hu Howard Mackey Ronald G. Thomas	1
+ PDF Chat	Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force	2021	Paul Aisen Randall J. Bateman María C. Carrillo Rachelle S. Doody Keith A. Johnson John R. Sims Reisa A. Sperling Bruno Vellas	1
+	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design	1992	Lars Frison Stuart J. Pocock	1
+ PDF Chat	Progression models for repeated measures: Estimating novel treatment effects in progressive diseases	2022	Lars Lau Rakêt	1
+	A new approach for estimating and quantifying disease‐modification in Alzheimer’s disease clinical trials	2022	Lars Lau Rakêt	1
+	Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis	2023	Melanie Quintana Benjamin R. Saville Matteo Vestrucci Michelle A. Detry Lori B. Chibnik Jeremy M. Shefner James Berry Marianne Chase Jinsy Andrews Alexander Sherman	1
+ PDF Chat	Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease	2024	Guoqiao Wang Yan Li Chengjie Xiong Tammie L.S. Benzinger Brian A. Gordon Jason Hassenstab Andrew J. Aschenbrenner Eric McDade David B. Clifford Jorge J. Libre‐Guerra	1
+	Novel non‐linear models for clinical trial analysis with longitudinal data: A tutorial using <scp>SAS</scp> for both frequentist and Bayesian methods	2024	Guoqiao Wang Whedy Wang Brian Mangal Yijie Liao Lon S. Schneider Yan Li Chengjie Xiong Eric McDade Richard Kennedy Randall J. Bateman	1
+ PDF Chat	Statistical considerations when estimating time‐saving treatment effects in Alzheimer's disease clinical trials	2024	Guoqiao Wang Gary Cutter Neil P. Oxtoby Guogen Shan Whedy Wang Brian Mangal Yijie Liao Jorge J. Llibre‐Guerra Li Y Chengjie Xiong	1
+	Measuring brain atrophy with a generalized formulation of the boundary shift integral	2014	Ferrán Prados M. Jorge Cardoso Kelvin K. Leung David M. Cash Marc Modat Nick C. Fox Claudia A. M. Gandini Wheeler‐Kingshott Sébastien Ourselin	1
+	Mixed model of repeated measures versus slope models in Alzheimer's disease clinical trials	2012	Michael Donohue Paul Aisen	1
+ PDF Chat	A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease	2015	Hong Liu‐Seifert Scott W. Andersen Ilya Lipkovich Karen C. Holdridge Eric Siemers	1
+	Fieller's Theorem, the Likelihood and the Delta Method	1990	Christopher Cox	1
+ PDF Chat	Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer’s disease	2011	Chengjie Xiong Gerald van Belle J. Philip Miller John C. Morris	1
+	The Delayed-Start Study Design	2009	Ralph B. D’Agostino	1
+	Direct effect on validity of response run-in selection in clinical trials	2003	Vance W. Berger Azadeh Rezvani Vanessa A Makarewicz	1